Medical treatment of hyperprolactinemia.
The current treatment of choice for primary hyperprolactinemia is medical. This is true not only for idiopathic forms, but also for micro- and macroprolactinomas, which are the most frequent causes of this pathology. Although questioned by some authors, the slow evolution of the illness, the rarity of transformation of a microadenoma into a macroadenoma, and the possibility of spontaneous cure cause most authors to favor medical treatment, with which they observe both normalization of gonadal function and tumor regression. By retrospective analysis of 95 hyperprolactinemic patients (72 women and 23 men including 26 cases of suspected microadenoma and 44 macroadenomas) treated with 3 dopamine agonists (bromocriptine, metergoline and CU 32085) between 1975 and 1983, and with the help of large series published in the literature, we have tried to review the present knowledge of this subject. After a quick review of different medications, we will consider their prolactin-suppressing effects, their influences upon gonadal and gonadotropic functions, and their antitumoral action. More specific problems will then be discussed: side effects, resistance, possibility of cure, the evolution of the prolactinoma, the place of medical therapy relative to surgery, and contraception in association with dopaminergics.
D000236:Adenoma / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D001971:Bromocriptine / Q000627:therapeutic use*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008297:Male; D010911:Pituitary Neoplasms / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D011379:Prognosis; D011388:Prolactin / Q000097:blood; D012016:Reference Values
D001971:Bromocriptine; D011388:Prolactin